Log in | Register

Obama to Seek More Alzheimer's Research Money

For the latest pharmaceutical news and updates - Sign up now!
Loading...

WASHINGTON (AP) — The Obama administration wants to spend just over half a billion dollars on Alzheimer's research next year, hoping to battle back against what could become the defining disease of the aging baby-boom generation.

Not all the spending must wait for approval from Congress: Under the plan being announced Tuesday, the National Institutes of Health will devote an extra $50 million to Alzheimer's research this year — opening the possibility that at least one stalled study of a possible therapy might get to start soon.

"The science of Alzheimer's disease has reached a very interesting juncture," with promising new findings to pursue after years of false starts, NIH Director Dr. Francis Collins told The Associated Press. "We would love to be able to come up with a way of bringing forward an even larger amount of support."

The NIH currently spends $450 million a year on Alzheimer's research. In his budget proposal to be released next week, President Barack Obama will ask Congress for $80 million in new money for Alzheimer's research next year, Collins said.

The move is part of the administration's development of the first National Alzheimer's Plan, a congressionally-ordered strategy that will combine research toward better dementia treatments with steps to help overwhelmed families to better cope today. In addition to biomedical research, the administration said it will propose spending $26 million for other goals of the still-to-be-finalized plan, including caregiver support.

"We can't wait to act," Health and Human Services Secretary Kathleen Sebelius said in a statement. "Reducing the burden of Alzheimer's disease on patients and their families is an urgent national priority."

Patient advocates long have said the nation's spending on Alzheimer's research is far too little considering the disease's coming toll. At a meeting last month some of the government's Alzheimer's advisers said it could take a research investment of as much as $2 billion a year to make a real impact.

"Our country cannot afford not to make these commitments," Alzheimer's Association President Harry Johns told that meeting.

More than 5 million Americans have Alzheimer's or related dementias, and, barring a medical breakthrough, that number is expected to more than double by 2050. Today, medical and nursing home bills for Alzheimer's total about $180 billion a year, a tab expected to reach $1 trillion.

For comparison, the government spends nearly $3 billion on AIDS research; about 1.1 million Americans are living with the AIDS virus.

Given the nation's fiscal problems, it's not clear what the chances are in Congress for a boost in Alzheimer's funding.

But for this year, Collins said Alzheimer's is such a priority that the NIH will shift some of its budget from other research areas to eke out an extra $50 million right away.

Among his examples: Some cutting-edge gene-mapping will be directed to concentrate on uncovering the genetics of Alzheimer's, including what protects the brains of some people in dementia-prone families. Collins also said he will determine whether the extra money is enough to start some clinical trials that otherwise would have to wait, including one to test whether an intranasal form of insulin might reach and protect the brain cells of people with early dementia symptoms.

 

 

Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter